Last Price
16.00
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Overview
Market Cap
0
Shares Outstanding
0
Avg Volume
0
Avg Price (50 Days)
0.00
Avg Price (200 Days)
0.00
PE Ratio
0.00
EPS
0.00
Earnings Announcement
Previous Close
0.00
Open
0.00
Day's Range
0.0 - 0.0
Year Range
0.0 - 0.0
Trading Volume
0
Price Change Highlight
1 Day Change
5 Day Change
1 Month Change
3 Month Change
6 Month Change
Ytd Change
1 Year Change
3 Year Change
5 Year Change
10 Year Change
Max Change
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
![[New IPO] PMCK Berhad, a healthcare services provider, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1180/Thumbnail__(7).png)
![[New IPO] ASM Automation Group Berhad, a F&B automation solutions provider, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1177/Thumbnail__(6).png)
![[New IPO] Pan Merchant Berhad, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1174/Thumbnail__(5).png)
Apps
Top Articles
1
Investment News
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
